Research suggests women with high breast cancer risk and menopausal symptoms could benefit from Duavee, which reduced breast ...

A new partnership between Hartford HealthCare and Pfizer is taking aim at migraines in the workplace. The innovative program ...

The Trump administration is eroding national pandemic flu defenses as it guts health agencies, cuts research and health ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Despite trading near decade-low valuations, Pfizer PFE is strategically repositioning itself for substantial long-term growth through its oncology transformation, particularly via the Seagen ...

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years. Shares are down 19% over ...